FibroGen, Inc.
409 Illinois Street
San Francisco
California
94158
United States
Tel: 415-978-1200
Website: http://www.fibrogen.com/
Email: info@fibrogen.com
About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
106 articles with FibroGen, Inc.
-
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.
-
FIBROGEN APPOINTS MAYKIN HO, PH.D., TO BOARD OF DIRECTORS
12/6/2018
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen’s Board of Directors.
-
AstraZeneca's Danilo Verge on Company's Cardiovascular, Renal and Metabolic Approach -- Interview
10/26/2018
AstraZeneca is presenting literally dozens of abstracts at this week’s American Society of Nephrology Kidney Week Annual Meeting in San Diego. Not only does it represent ongoing research on already approved drugs, but promising pipeline products. -
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
-
FibroGen Reports Third Quarter 2017 Financial Results
11/9/2017
FibroGen will host a conference call and webcast today, November 8, 2017, at 5:00 p.m. ET to discuss financial results and provide a business update.
-
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017
10/31/2017
The company will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).
-
Week in Review: WuXi AppTec Acquires US-Global Clinical CRO
10/23/2017
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
-
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
10/18/2017
The NDA submission triggers a $15 million milestone payment, payable to FibroGen by AstraZeneca.
-
FibroGen Appoints Gerald Lema To Board Of Directors
9/20/2017
-
FibroGen Presents Latest Data From Phase IIb Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis At European Respiratory Society (ERS) International Congress 2017
9/13/2017
-
FibroGen Announces Pricing Of Follow-On Offering Of Common Stock
8/16/2017
-
FibroGen Announces Proposed Follow-On Offering Of Common Stock
8/15/2017
-
FibroGen Reports Second Quarter 2017 Financial Results
8/8/2017
-
FibroGen Announces Positive Topline Results From Phase II Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis
8/8/2017
-
FibroGen To Report Second Quarter Financial Results On Monday, August 7, 2017
8/1/2017
-
FibroGen Granted Orphan Drug Designation For Pamrevlumab In The Treatment Of Pancreatic Cancer
6/22/2017
-
European Patent Office Maintains FibroGen Patent Relating To Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
6/5/2017